The Impact of Endothelial Dysfunction on the Course of Metabolically Associated Liver Disease in Combination with Subclinical Hypothyroidism
Main Article Content
Abstract
Background. Intrahepatic endothelial dysfunction is involved in many diseases, including fatty liver disease, and in combination with other numerous mechanisms may play a role in atherosclerosis in hypothyroidism. It is possible that endothelial dysfunction markers may be important in assessing the risk of cardiovascular events in patients with metabolic-associated fatty liver disease (MAFLD) in combination with subclinical hypothyroidism.
Aims. The aim of this study was to evaluate changes in endothelial dysfunction markers in patients with MAFLD in combination with subclinical hypothyroidism.
Methods. We studied 298 patients aged 40-69 years with a history of MAFLD. Of these, 128 patients had a verified diagnosis of both MAFLD and subclinical hypothyroidism. In such cases, the morphological state of the vascular endothelium was assessed by counting circulating desquamated epithelial cells (CDEC) and vascular endothelial growth factor (VEGF-A) in the blood using phase-contrast microscopy and the value of these parameters was in comparison todepending on the level of thyroid stimulating hormone, insulin, age, and cardiovascular risk.
Results. It was found that the level of CDEC and VEGF-A was increased in patients with MAFLD and subclinical hypothyroidism. On the one hand, thyroid stimulating hormone levels were found to be associated with endothelial dysfunction and hyperinsulinemia. On the other hand, endothelial dysfunction indices also have links with the degree of cardiovascular risk. Patients with moderate and high cardiovascular risk have a relationship between CDEC and levels of triglycerides, C-reactive protein, and сardiovascular diseases. The levels of VEGF-A and CDEC were significantly higher in the adult age group. VEGF-A levels > 273 pg/mL were associated with abnormalities in the studied parameters, including those reflecting of the liver.
Conclusion. Patients with MAFLD in combination with hypertension have elevated levels of CDEC and VEGF-A, which affects the involvement of these factors in the mechanisms of endothelial dysfunction in this category. Markers of endothelial dysfunction can be used to assess the prediction of possible cardiometabolic risk.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Clyne AM. Endothelial response to glucose: dysfunction, metabolism, and transport. Biochem Soc Trans. 2021;49(1):313-325. doi:10.1042/BST20200611
3. Falkevall A, Mehlem A, Folestad E, et al. Inhibition of VEGF-A-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue. J Hepatol. 2023;78(5):901-913. doi: 10.1016/j.jhep.2023.01.014.
4. Hammoutene A, Rautou P.E. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J Hepatol. 2019;70(6):1278-1291. doi:10.1016/j.jhep.2019.02.012
5. Saif A, Mousa S, Assem M, Tharwat N, Abdelhamid A. Endothelial dysfunction and the risk of atherosclerosis in overt and subclinical hypothyroidism. Endocr Connect. 2018;7(10):1075-1080. doi:10.1530/EC-18-0194
6. Borges JP, Lopes GO, Verri V, et al. A novel effective method for the assessment of microvascular function in male patients with coronary artery disease: a pilot study using laser speckle contrast imaging. Braz J Med Biol Res. 2016;49(10):e5541. doi:10.1590/1414-431X20165541
7. Pasarín M, Abraldes JG, Liguori E, Kok B, La Mura V. Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction. World J Gastroenterol. 2017;23(37):6777-6787. doi:10.3748/wjg.v23.i37.6777
8. Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021;3(5):100322. doi: 10.1016/j.jhepr.2021.100322
9. Wiersinga WM. Guidance in Subclinical Hyperthyroidism and Subclinical Hypothyroidism: Are We Making Progress? Eur Thyroid J. 2015;4(3):143-148. doi:10.1159/000438909
10. Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3-10. doi:10.1016/j.ejim.2023.11.005
11. Ciccone MM, De Pergola G, Porcelli MT, et al. Increased carotid IMT in overweight and obese women affected by Hashimoto's thyroiditis: an adiposity and autoimmune linkage?. BMC Cardiovasc Disord. 2010;10:22. Published 2010 May 28. doi:10.1186/1471-2261-10-22
12. Cho KI, Lee JH. The impact of thyroid autoimmunity on arterial stiffness in postmenopausal patients with fibromyalgia. Int J Rheum Dis. 2017;20(12):1978-1986. doi:10.1111/1756-185X.12257
13. Foglia B, Sutti S, Pedicini D, et al. Oncostatin M, a profibrogenic mediator overexpressed in non-alcoholic fatty liver disease, stimulates migration of hepatic myofibroblasts. Cells. 2019;9(1):28. doi:10.3390/cells9010028
14. Shen H, Yu H, Li QY, et al. Hepatocyte-derived VEGF-AA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells. Acta Pharmacol Sin. 2022;43(11):2917–2928. doi:10.1038/s41401-022-00907-5
15. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2010;11(6):430-445. doi:10.1111/j.1467-789X.2009.00657.x
16. Nasiri-Ansari N, Androutsakos T, Flessa CM, et al. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (MAFLD): A Concise Review. Cells. 2022;11(16):2511. doi:10.3390/cells11162511
17. Meza CA, La Favor JD, Kim DH, Hickner RC. Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS? Int J Mol Sci. 2019;20(15):3775. doi:10.3390/ijms20153775
18. Niknam N, Khalili N, Khosravi E, Nourbakhsh M. Endothelial dysfunction in patients with subclinical hypothyroidism and the effects of treatment with levothyroxine. Adv Biomed Res. 2016;5:38. doi:10.4103/2277-9175.178783
19. Tseng FY, Lin WY, Lin CC, et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol. 2012;60(8):730-737. doi:10.1016/j.jacc.2012.03.047
20. Liu FH, Hwang JS, Kuo CF, Ko YS, Chen ST, Lin JD. Subclinical hypothyroidism and metabolic risk factors association: A health examination-based study in northern Taiwan. Biomed J. 2018;41(1):52-58. doi: 10.1016/j.bj.2018.02.002
21. Lopez-Yus M, Hörndler C, Borlan S, Bernal-Monterde V, Arbones-Mainar JM. Unraveling Adipose Tissue Dysfunction: Molecular Mechanisms, Novel Biomarkers, and Therapeutic Targets for Liver Fat Deposition. Cells. 2024;13(5):380.
doi:10.3390/cells13050380
22. Raposo L, Martins S, Ferreira D, Guimarães JT, Santos AC. Metabolic Syndrome, Thyroid Function and Autoimmunity - The PORMETS Study. Endocr Metab Immune Disord Drug Targets. 2019;19(1):75-83.
doi: 10.2174/1871530318666180801125258